Dendritic cell adhesion is enhanced on endothelial cells preexposed to calcineurin inhibitors

Journal of Cardiovascular Pharmacology

Volumn 46, Issue 3, 2005, Pages 250-254

  Schlichting, Christoph L ^a   Schareck, Wolfgang D ^a   Weis, Michael ^b  

^a ROSTOCK UNIVERSITY MEDICAL CENTER   (Germany)

^b LUDWIG MAXIMILIANS UNIVERSITY   (Germany)

Author keywords

Chronic rejection; Cyclosporine A; Endothelium; Inflammation; Tacrolimus; Transplantation

Indexed keywords

BLOCKING ANTIBODY; CALCINEURIN INHIBITOR; CD14 ANTIGEN; CD31 ANTIGEN; CYCLOSPORIN A; GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR; INTERCELLULAR ADHESION MOLECULE 1; INTERLEUKIN 4; LYMPHOCYTE FUNCTION ASSOCIATED ANTIGEN 1; TACROLIMUS; VASCULAR CELL ADHESION MOLECULE 1;

ARTICLE; CELL ADHESION; CELL MIGRATION; CHRONIC GRAFT REJECTION; CONTROLLED STUDY; DENDRITIC CELL; ENDOTHELIUM CELL; HUMAN; HUMAN CELL; IMMUNOSUPPRESSIVE TREATMENT; MONOCYTE; PRIORITY JOURNAL;

ANTIBODIES, BLOCKING; ANTIBODIES, MONOCLONAL; ANTIGENS, CD14; CALCINEURIN; CELL ADHESION; CELL ADHESION MOLECULES; CELL MOVEMENT; CYCLOSPORINE; DENDRITIC CELLS; ENDOTHELIAL CELLS; ENZYME INHIBITORS; GRAFT REJECTION; GRANULOCYTE-MACROPHAGE COLONY-STIMULATING FACTOR; HUMANS; IMMUNOSUPPRESSIVE AGENTS; INTERLEUKIN-4; TACROLIMUS;

EID: 24344439714     PISSN: 01602446     EISSN: None     Source Type: Journal    
DOI: 10.1097/01.fjc.0000175233.88207.de     Document Type: Article

References (27)

1. Nikaein A, Backman L, Jennings L, et al. HLA compatibility and liver transplant outcome. Improved patient survival by HLA and cross-matching. Transplantation. 1994;58:786-792.
2. Opelz G. HLA matching analysis of cyclosporine-treated cadaver kidneys transplanted in 1986. Transplant Proc. 1987;19:3557-3558.
3. European FK506 Multicentre Liver Study Group. Randomised trial comparing tacrolimus (FK506) and cyclosporin in prevention of liver allograft rejection. Lancet. 1994;344:423-428.
4. van Saase JL, van der Woude FJ, Thorogood J, et al. The relation between acute vascular and interstitial renal allograft rejection and subsequent chronic rejection. Transplantation. 1995;59:1280-1285.
5. Sonoda T, Takahara S, Takahashi K, et al. Outcome of 3 years of immunosuppression with tacrolimus in more than 1,000 renal transplant recipients in Japan. Transplantation. 2003;75:199-204.
6. Weis M, von Scheldt W. Coronary artery disease in the transplanted heart. Annu Rev Med. 2000;51:81-100.
7. Moien-Afshari F, McManus BM, Laher I. Immunosuppression and transplant vascular disease: benefits and adverse effects. Pharmacol Ther. 2003;100:141-156.
8. Boots JMM, Christiaans MHL, Hoof JP. Effect of immunosuppressive agents on long-term survival of renal transplant recipients. Drugs. 2004; 64:2047-2073.
9. Lechler R, Ng WF, Steinman RM. Dendritic cells in transplantation-friend or foe? Immunity. 2001;14:357-368.
10. Penfield JG, Dawidson IA, Ar'Rajab A, et al. Syngeneic renal transplantation increases the number of renal dendritic cells in the rat. Transpl Immunol. 1999;7:197-200.
11. Weis M, Schlichting CL, Engleman EG, et al. Endothelial determinants of dendritic cell adhesion and migration: new implications for vascular diseases. Arterioscler Thromb Vasc Biol. 2002;22:1817-1823.
12. Muller WA, Weigl SA, Deng X, et al. PECAM-1 is required for transendothelial migration of leukocytes. J Exp Med. 1993;178:449-460.
13. Meyer DM, Dustin ML, Carron CP. Characterization of intercellular adhesion molecule-1 ectodomain (sICAM-1) as an inhibitor of lymphocyte function-associated molecule-1 interaction with ICAM-1. J Immunol. 1995;155:3578-3584.
14. Weis M, von Scheldt W. Cardiac allograft vasculopathy: a review. Circulation. 1997;96:2069-2077.
15. Weis M, Pehlivanli S, von Scheldt W. Heart allograft endothelial cell dysfunction. Cause, course, and consequences. Z Kardiol. 2000;89(Suppl 9):IX/58-IX/62.
16. Weis M, Wildhirt SM, Schulze C, et al. Coronary vasomotor dysfunction in the cardiac allograft: impact of different immunosuppressive regimens. J Cardiovasc Pharmacol. 2000;36:776-784.
17. Trapp A, Weis M. Immunosuppression and endothelial function. J Cardiovasc Pharmacol. 2005;45:81-87.
18. Cos J, Villalba T, Parra R, et al. FK506 in the maturation of dendritic cells. Haematologica. 2002;87:679-687.
19. Bachmann MF, McKall-Faienza K, Schmits R, et al. Distinct roles for LFA-1 and CD28 during activation of naive T cells: adhesion versus costimulation. Immunity. 1997;7:549-557.
20. Woo J, Propper DJ, Thomson AW. Antigen presentation and HLA-DR expression by FK-506-treated human monocytes. Immunology. 1990;71:551-555.
21. Dumont FJ, Staruch MJ, Koprak SL, et al. Distinct mechanisms of suppression of murine T cell activation by the related macrolides FK-506 and rapamycin. J Immunol. 1990;144:251-258.
22. Markovic S, Raab M, Daxecker H, et al. In vitro effects of cyclosporin A on the expression of adhesion molecules on human umbilical vein endothelial cells. Clin Chim Acta. 2002;316:25-31.
23. Rafiee P, Johnson CP, Li MS, et al. Cyclosporine A enhances leukocyte binding by human intestinal microvascular endothelial cells through inhibition of p38 MAPK and iNOS. Paradoxical proinflammatory effect on the microvascular endothelium. J Biol Chem. 2002;277:35605-35615.
24. D'Amico G, Bianchi G, Bernasconi S, et al. Adhesion, transendothelial migration, and reverse transmigration of in vitro cultured dendritic cells. Blood. 1998;92:207-214.
25. Nicolls MR, Coulombe M, Beilke J, et al. CD4-dependent generation of dominant transplantation tolerance induced by simultaneous perturbation of CD154 and LFA-1 pathways. J Immunol. 2002;169:4831-4839.
26. Karlsson H, Nassberger L. FK506 suppresses the mitogen-induced increase in lymphocyte adhesiveness to endothelial cells, but does not affect endothelial cell activation in response to inflammatory stimuli. Transplantation. 1997;64:1217-1220.
27. Papaccio G, Latronico MV, Graziano A, et al. Tacrolimus, but not cyclosporine A, significantly increases expression of ICAM-1 and IFN-gamma in the NOD mouse. J Cell Biochem Suppl. 2001;(Suppl 36):107-116.